Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 3/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28585298 | 0.86 | FFAR1 (0.51) | FFAR1FFAR4GRM5SIGMAR1MAOA | |
| SCHEMBL24922969 | 0.84 | FFAR1 (0.50) | FFAR1FFAR4GRM5SIGMAR1 | |
| SCHEMBL29187194 | 0.81 | GRM5 (0.54) | FFAR1FFAR4GRM5SIGMAR1MAOA | |
| SCHEMBL16010836 | 0.81 | FFAR1 (0.55) | FFAR1FFAR4GRM5 | |
| SCHEMBL7504948 | 0.81 | FFAR1 (0.61) | FFAR1FFAR4GRM5SIGMAR1 | |
| SCHEMBL24925945 | 0.80 | FFAR1 (0.47) | FFAR1FFAR4GRM5SIGMAR1 | |
| SCHEMBL37703522 | 0.80 | GRM5 (0.49) | FFAR1FFAR4GRM5SIGMAR1 | |
| SCHEMBL16010932 | 0.78 | FFAR1 (0.49) | FFAR1FFAR4GRM5SIGMAR1 | |
| SCHEMBL21163945 | 0.78 | FFAR1 (0.49) | FFAR1FFAR4GRM5NAAAMIF | |
| SCHEMBL27508668 | 0.78 | FFAR1 (0.46) | FFAR1FFAR4GRM5SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117715912-B | Macrocyclic ligands with picolinate groups, complexes thereof and medical uses | 法国加柏公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4377316-B1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND MEDICAL USES THEREOF | GUERBET SA (FR) | 2025-12-03 | — | — | EP | disclosed |
| US-20240352011-A1 | Macrocyclic Ligands with Picolinate Group(s), Complexes and Medical Uses Thereof | GUERBET (FR) | 2024-10-24 | — | — | US | disclosed |
| EP-4124361-B1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND MEDICAL USES THEREOF | GUERBET SA (FR) | 2024-01-31 | — | — | EP | disclosed |
| WO-2023006938-A1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES AND MEDICAL USES THEREOF | GUERBET (FR) | 2023-02-02 | — | — | WO | disclosed |
| EP-4124361-A1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND MEDICAL USES THEREOF | Guerbet (FR) | 2023-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352011-A1 | Macrocyclic Ligands with Picolinate Group(s), Complexes and Medical Uses Thereof | MPI, GRPR, SSTR3 | FFAR1 1057/4885FFAR4 781/4885GRM5 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.